首页 > 最新文献

Interdisciplinary cardiovascular and thoracic surgery最新文献

英文 中文
Mid-term outcomes of tricuspid annuloplasty using the Tri-Ad Adams tricuspid annuloplasty ring. 使用 Tri-Ad adams 三尖瓣瓣环成形术的中期效果。
N/A CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-07-03 DOI: 10.1093/icvts/ivae131
Heemoon Lee, Jihoon Kim, Ji-Hyun Jung, Jae Suk Yoo

Objectives: The Tri-Ad Adams tricuspid annuloplasty ring is a recent innovative prosthesis characterized by a semi-rigid central component and fully flexible extremities. The goal of this study was to assess the short-term and mid-term results following implantation of the Tri-Ad Adams ring.

Methods: A retrospective analysis was conducted on patients who underwent tricuspid annuloplasty using the Tri-Ad Adams ring between August 2016 and October 2021.

Results: Our study enrolled a total of 248 participants. The median age was 64.0 (interquartile range: 56.0-71.5) years. The median EuroSCORE II was 4.3% (2.7-7.5%), with 37 patients (14.9%) having a history of cardiac operations. Tricuspid regurgitation of grade 2-3 was observed in 63.7% of cases, and the median tricuspid annular diameter was 3.3 (2.8-3.6) cm. Concurrent procedures included mitral valve replacement (n = 160, 64.5%), mitral valve repair (n = 75, 30.2%), aortic valve replacement (n = 72, 29.0%) and the maze procedure (n = 170, 68.5%). Immediate postoperative tricuspid regurgitation≥moderate was present in 1 patient (0.4%). Early death occurred in 14 patients (5.6%). Major complications included low cardiac output syndrome (n = 18, 0.3%), acute kidney injury (n = 14, 5.6%) and permanent pacemaker placement (n = 15, 6.0%). According to the Kaplan-Meier analysis, the 4-year rates of freedom from overall mortality and moderate-to-severe tricuspid regurgitation were 96.9% and 91.6%, respectively. There were no incidents of tricuspid valve reoperations, ring detachment or significant tricuspid stenosis (trans-tricuspid valve gradient ≥ 5 mmHg).

Conclusions: Tricuspid annuloplasty utilizing the Tri-Ad Adams ring demonstrated favourable outcomes in both the early and midterm periods. Further studies are warranted to confirm the long-term results.

目的:Tri-Ad Adams 三尖瓣瓣环成形术(明尼苏达州明尼阿波利斯市美敦力公司)是一种最新的创新型假体,其特点是中央部分半刚性,而四肢完全柔性。本研究旨在评估植入 Tri-Ad Adams 环后的短期和中期效果:方法:对2016年8月至2021年10月期间使用Tri-Ad Adams环进行三尖瓣环成形术的患者进行回顾性分析:我们的研究共招募了 248 名参与者。中位年龄为 64.0 岁(四分位距:56.0-71.5)。EuroSCORE II 的中位数为 4.3 (2.7-7.5%)%,37 名患者(14.9%)曾接受过心脏手术。63.7%的病例出现2-3级三尖瓣反流,三尖瓣环直径中位数为3.3(2.8-3.6)厘米。同时进行的手术包括二尖瓣置换术(60 例,占 64.5%)、二尖瓣修复术(75 例,占 30.2%)、主动脉瓣置换术(72 例,占 29.0%)和迷宫术(170 例,占 68.5%)。术后立即出现三尖瓣反流≥中度的患者有 1 例(0.4%)。14名患者(5.6%)出现早期死亡。主要并发症包括低心排血量综合征(18 例,0.3%)、急性肾损伤(14 例,5.6%)和永久起搏器置入(15 例,6.0%)。根据 Kaplan-Meier 分析,四年内无总死亡率和无中度至重度三尖瓣反流率分别为 96.9% 和 91.6%。没有发生三尖瓣再手术、瓣环脱落或严重三尖瓣狭窄(跨三尖瓣梯度≥5 mmHg):使用 Tri-Ad Adams 环进行三尖瓣瓣环成形术在早期和中期都有良好的疗效。有必要进行进一步研究,以确认长期结果。
{"title":"Mid-term outcomes of tricuspid annuloplasty using the Tri-Ad Adams tricuspid annuloplasty ring.","authors":"Heemoon Lee, Jihoon Kim, Ji-Hyun Jung, Jae Suk Yoo","doi":"10.1093/icvts/ivae131","DOIUrl":"10.1093/icvts/ivae131","url":null,"abstract":"<p><strong>Objectives: </strong>The Tri-Ad Adams tricuspid annuloplasty ring is a recent innovative prosthesis characterized by a semi-rigid central component and fully flexible extremities. The goal of this study was to assess the short-term and mid-term results following implantation of the Tri-Ad Adams ring.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on patients who underwent tricuspid annuloplasty using the Tri-Ad Adams ring between August 2016 and October 2021.</p><p><strong>Results: </strong>Our study enrolled a total of 248 participants. The median age was 64.0 (interquartile range: 56.0-71.5) years. The median EuroSCORE II was 4.3% (2.7-7.5%), with 37 patients (14.9%) having a history of cardiac operations. Tricuspid regurgitation of grade 2-3 was observed in 63.7% of cases, and the median tricuspid annular diameter was 3.3 (2.8-3.6) cm. Concurrent procedures included mitral valve replacement (n = 160, 64.5%), mitral valve repair (n = 75, 30.2%), aortic valve replacement (n = 72, 29.0%) and the maze procedure (n = 170, 68.5%). Immediate postoperative tricuspid regurgitation≥moderate was present in 1 patient (0.4%). Early death occurred in 14 patients (5.6%). Major complications included low cardiac output syndrome (n = 18, 0.3%), acute kidney injury (n = 14, 5.6%) and permanent pacemaker placement (n = 15, 6.0%). According to the Kaplan-Meier analysis, the 4-year rates of freedom from overall mortality and moderate-to-severe tricuspid regurgitation were 96.9% and 91.6%, respectively. There were no incidents of tricuspid valve reoperations, ring detachment or significant tricuspid stenosis (trans-tricuspid valve gradient ≥ 5 mmHg).</p><p><strong>Conclusions: </strong>Tricuspid annuloplasty utilizing the Tri-Ad Adams ring demonstrated favourable outcomes in both the early and midterm periods. Further studies are warranted to confirm the long-term results.</p>","PeriodicalId":73406,"journal":{"name":"Interdisciplinary cardiovascular and thoracic surgery","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11334059/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141602336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A clinical nomogram for predicting occult lymph node metastasis in patients with non-small-cell lung cancer ≤2 cm. 预测非小细胞肺癌≤2 厘米患者隐匿性淋巴结转移的临床提名图。
N/A CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-07-03 DOI: 10.1093/icvts/ivae098
Jiangshan Ai, Huijiang Gao, Guodong Shi, Yaliang Lan, Shiyu Hu, Zhaofeng Wang, Lin Liu, Yucheng Wei

Objectives: Sublobar resection has been shown to be feasible for non-small-cell lung cancers (NSCLC) <2 cm in size based on several prospective studies. However, the prognosis of clinical N0 patients who experience an N-stage upgrade after surgery [known as occult lymph node metastasis (OLM)] may be worse. The ability of predict OLM in patients eligible for sublobar resection remains a controversial issue.

Methods: Patients with NSCLC ≤2 cm in diameter and containing a solid component who underwent surgical treatment at the Affiliated Hospital of Qingdao University were retrospectively enrolled, and 1:1 case matching was performed. The risk factors were identified through logistic regression analyses and theoretical criteria, followed by the development of a nomogram that was evaluated using 200 iterations of 10-fold cross-validation.

Results: After case matching, 130 pairs of patients were selected for modelling. According to the multivariable logistic regression analysis, the carcinoembryonic antigen level, consolidation tumour ratio, mean computed tomography number and tumour margin were included in the nomogram. The cross-validated average area under the receiver operating characteristic curve was found to be 0.86. Furthermore, calibration curve and decision curve analyses demonstrated the excellent predictive accuracy and clinical utility of the nomogram respectively.

Conclusions: By utilizing accessible characteristics, we developed a nomogram that predicts the probability of OLM in patients with NSCLC ≤2 cm with a solid component. Risk stratification with this nomogram could aid in surgical method decision-making.

Clinical registration number: Not applicable.

目的:多项前瞻性研究表明,对小于 2 厘米的非小细胞肺癌进行叶下切除术是可行的。然而,临床 N0 期患者术后出现 N 期升级(称为隐匿性淋巴结转移)的预后可能会更差。如何预测符合亚肺叶切除术条件的患者的隐匿性淋巴结转移仍是一个有争议的问题:方法:回顾性纳入在青岛大学附属医院接受外科手术治疗的直径≤2厘米且含有实体成分的非小细胞肺癌患者,并进行1:1病例配对。通过逻辑回归分析和理论标准确定风险因素,然后制定提名图,并通过 200 次迭代的 10 倍交叉验证进行评估:结果:经过病例配对,130 对患者被选中进行建模。根据多变量逻辑回归分析,癌胚抗原水平、合并肿瘤比率、计算机断层扫描平均值和肿瘤边缘均被纳入提名图。交叉验证后发现,接收者操作特征曲线下的平均面积为 0.86。此外,校准曲线和决策曲线分析分别证明了提名图极佳的预测准确性和临床实用性:通过利用可获得的特征,我们开发出了一种提名图,可预测≤2厘米且有实性成分的NSCLC患者发生隐匿性淋巴结转移的概率。利用该提名图进行风险分层有助于手术方法的决策。
{"title":"A clinical nomogram for predicting occult lymph node metastasis in patients with non-small-cell lung cancer ≤2 cm.","authors":"Jiangshan Ai, Huijiang Gao, Guodong Shi, Yaliang Lan, Shiyu Hu, Zhaofeng Wang, Lin Liu, Yucheng Wei","doi":"10.1093/icvts/ivae098","DOIUrl":"10.1093/icvts/ivae098","url":null,"abstract":"<p><strong>Objectives: </strong>Sublobar resection has been shown to be feasible for non-small-cell lung cancers (NSCLC) <2 cm in size based on several prospective studies. However, the prognosis of clinical N0 patients who experience an N-stage upgrade after surgery [known as occult lymph node metastasis (OLM)] may be worse. The ability of predict OLM in patients eligible for sublobar resection remains a controversial issue.</p><p><strong>Methods: </strong>Patients with NSCLC ≤2 cm in diameter and containing a solid component who underwent surgical treatment at the Affiliated Hospital of Qingdao University were retrospectively enrolled, and 1:1 case matching was performed. The risk factors were identified through logistic regression analyses and theoretical criteria, followed by the development of a nomogram that was evaluated using 200 iterations of 10-fold cross-validation.</p><p><strong>Results: </strong>After case matching, 130 pairs of patients were selected for modelling. According to the multivariable logistic regression analysis, the carcinoembryonic antigen level, consolidation tumour ratio, mean computed tomography number and tumour margin were included in the nomogram. The cross-validated average area under the receiver operating characteristic curve was found to be 0.86. Furthermore, calibration curve and decision curve analyses demonstrated the excellent predictive accuracy and clinical utility of the nomogram respectively.</p><p><strong>Conclusions: </strong>By utilizing accessible characteristics, we developed a nomogram that predicts the probability of OLM in patients with NSCLC ≤2 cm with a solid component. Risk stratification with this nomogram could aid in surgical method decision-making.</p><p><strong>Clinical registration number: </strong>Not applicable.</p>","PeriodicalId":73406,"journal":{"name":"Interdisciplinary cardiovascular and thoracic surgery","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11226880/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141077361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Severe aortic stenosis treated with transcatheter aortic valve implantation or surgical aortic valve replacement with Perimount in Western Denmark 2016-2022: a nationwide retrospective study. 2016-2022 年丹麦西部采用经导管主动脉瓣植入术或外科主动脉瓣置换术治疗的重度主动脉瓣狭窄:一项全国范围的回顾性研究。
N/A CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-07-03 DOI: 10.1093/icvts/ivae122
Lytfi Krasniqi, Axel Brandes, Poul Erik Mortensen, Oke Gerke, Lars Riber

Objectives: The healthcare registries in Denmark present a unique opportunity to gain novel insights into the outcomes associated with both transcatheter and surgical approaches to aortic valve replacement. Our objective is to enhance shared decision-making by comparing long-term mortality and clinical outcomes between treatments.

Methods: This observational study included all patients with severe aortic stenosis undergoing elective isolated transfemoral transcatheter aortic valve implantation (TAVI) or surgical aortic valve replacement (SAVR) in Western Denmark between January 2016 and April 2022. Patient population and clinical data were identified from the Western Danish Heart Registry and the National Danish Patient Registry, respectively. A propensity score-matched population was generated. Outcomes were investigated according to Valve Academic Research Consortium-3.

Results: A total of 2269 TAVI patients and 1094 SAVR patients where identified. The propensity score-matched population consisted of 468 TAVI patients (mean[SD]age, 75.0[5.3] years) and 468 SAVR patients (mean[SD] age, 75.1[4.6]years). The Kaplan-Meier estimate for the 5-year all-cause mortality was 29.8% in the TAVI group and 16.9% for in the SAVR group (P = 0.019). The risk of all stroke or transient ischaemic attack after five year was 15.1% in the TAVI group and 11.0% in the SAVR group (P = 0.047).

Conclusions: This study underscores the importance of evaluating all patient factors when choosing an aortic valve replacement method. Surgical aortic valve replacement was an excellent choice, especially for patients with New York Heart Association class I/II, ≥75 age, left ventricular ejection fraction ≥50%, or longer life expectancy.

目的:丹麦的医疗保健登记为我们提供了一个独特的机会,让我们能够深入了解经导管主动脉瓣置换术和手术主动脉瓣置换术的相关结果。我们的目标是通过比较两种治疗方法的长期死亡率和临床疗效来加强共同决策:这项观察性研究纳入了2016年1月至2022年4月期间在丹麦西部接受择期孤立经股动脉导管主动脉瓣植入术(TAVI)或外科主动脉瓣置换术(SAVR)的所有重度主动脉瓣狭窄患者。患者人群和临床数据分别来自丹麦西部心脏登记处和丹麦全国患者登记处。生成了倾向评分匹配人群。结果根据瓣膜学术研究联盟-3(Valve Academic Research Consortium-3)进行调查:结果:共确定了 2269 名 TAVI 患者和 1094 名 SAVR 患者。倾向得分匹配人群包括 468 名 TAVI 患者(平均[标码]年龄,75.0[5.3]岁)和 468 名 SAVR 患者(平均[标码]年龄,75.1[4.6]岁)。TAVI 组 5 年全因死亡率的 Kaplan-Meier 估计值为 29.8%,SAVR 组为 16.9%(P = 0.019)。五年后中风或短暂性脑缺血发作的风险在TAVI组为15.1%,在SAVR组为11.0%(P = 0.047):这项研究强调了在选择主动脉瓣置换方法时评估患者所有因素的重要性。手术主动脉瓣置换术是一种可行的选择,尤其是对于纽约心脏协会I/II级、年龄≥75岁、左室射血分数≥50%或预期寿命较长的患者。
{"title":"Severe aortic stenosis treated with transcatheter aortic valve implantation or surgical aortic valve replacement with Perimount in Western Denmark 2016-2022: a nationwide retrospective study.","authors":"Lytfi Krasniqi, Axel Brandes, Poul Erik Mortensen, Oke Gerke, Lars Riber","doi":"10.1093/icvts/ivae122","DOIUrl":"10.1093/icvts/ivae122","url":null,"abstract":"<p><strong>Objectives: </strong>The healthcare registries in Denmark present a unique opportunity to gain novel insights into the outcomes associated with both transcatheter and surgical approaches to aortic valve replacement. Our objective is to enhance shared decision-making by comparing long-term mortality and clinical outcomes between treatments.</p><p><strong>Methods: </strong>This observational study included all patients with severe aortic stenosis undergoing elective isolated transfemoral transcatheter aortic valve implantation (TAVI) or surgical aortic valve replacement (SAVR) in Western Denmark between January 2016 and April 2022. Patient population and clinical data were identified from the Western Danish Heart Registry and the National Danish Patient Registry, respectively. A propensity score-matched population was generated. Outcomes were investigated according to Valve Academic Research Consortium-3.</p><p><strong>Results: </strong>A total of 2269 TAVI patients and 1094 SAVR patients where identified. The propensity score-matched population consisted of 468 TAVI patients (mean[SD]age, 75.0[5.3] years) and 468 SAVR patients (mean[SD] age, 75.1[4.6]years). The Kaplan-Meier estimate for the 5-year all-cause mortality was 29.8% in the TAVI group and 16.9% for in the SAVR group (P = 0.019). The risk of all stroke or transient ischaemic attack after five year was 15.1% in the TAVI group and 11.0% in the SAVR group (P = 0.047).</p><p><strong>Conclusions: </strong>This study underscores the importance of evaluating all patient factors when choosing an aortic valve replacement method. Surgical aortic valve replacement was an excellent choice, especially for patients with New York Heart Association class I/II, ≥75 age, left ventricular ejection fraction ≥50%, or longer life expectancy.</p>","PeriodicalId":73406,"journal":{"name":"Interdisciplinary cardiovascular and thoracic surgery","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11229432/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141473261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of smoking on resected lung cancer depends on epidermal growth factor receptor mutation. 吸烟对切除肺癌的影响取决于表皮生长因子受体突变。
N/A CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-07-03 DOI: 10.1093/icvts/ivae109
Keigo Sekihara, Akikazu Kawase, Yuta Matsubayashi, Tomoya Tajiri, Motohisa Shibata, Takamitsu Hayakawa, Norihiko Shiiya, Kazuhito Funai

Objectives: Smokers comprise the majority of surgical patients with primary lung cancer. Epidermal growth factor receptor (EGFR) mutation-negative status impacts the treatment of recurrence. However, the prognostic impact of cigarette smoking stratified by EGFR mutation status has not been reported. Therefore, we assessed its impact on patients with resected lung cancer.

Methods: We retrospectively analysed 362 consecutive patients who underwent complete resection for stage 1 primary lung cancer at our institution between 2012 and 2021. The EGFR mutation status was evaluated using the real-time polymerase chain reaction. We compared the overall survival (OS) and disease-free survival (DFS) between patients with and without a history of smoking.

Results: The EGFR mutation-negative group included 194 patients, of whom 160 (83%) had a history of smoking. Male sex (P < 0.01), forced expiratory volume in 1 s (P < 0.01) and adenocarcinoma (P < 0.01) showed significant differences between the groups. In the EGFR mutation-positive group, the 5-year OS and DFS were similar regardless of smoking status (OS: 86% vs 75%; DFS: 73% vs 73%). In the EGFR mutation-negative group, the 5-year OS and DFS were significantly poorer in the smoking group (OS: 87% vs 65%, P = 0.05; DFS: 84% vs 54%, P = 0.01). Deaths from other diseases were relatively high (n = 19, 53%).

Conclusions: Cigarette smoking may be associated with a poor prognosis in EGFR mutation-negative lung cancer but had no impact on the prognosis of the EGFR mutation-positive group. This finding underscores the potential influence of smoking on the treatment of lung cancer recurrence but also highlights its significance in contributing to death from other diseases.

目的:吸烟者占原发性肺癌外科患者的大多数。表皮生长因子受体(EGFR)突变阴性状态会影响复发治疗。然而,根据表皮生长因子受体(EGFR)突变状态分层的吸烟对预后的影响尚未见报道,我们对切除肺癌患者的吸烟影响进行了评估:我们回顾性分析了 2012 年至 2021 年期间在我院接受完全切除术的 362 例 I 期原发性肺癌患者。采用实时聚合酶链反应评估表皮生长因子受体(EGFR)突变状态。我们比较了有吸烟史和无吸烟史患者的总生存期(OS)和无病生存期(DFS):结果:表皮生长因子受体突变阴性组包括 194 名患者,其中 160 人(83%)有吸烟史。男性(P吸烟可能与表皮生长因子受体突变阴性肺癌的不良预后有关,但对表皮生长因子受体突变阳性组的预后没有影响。这一发现强调了吸烟对肺癌复发治疗的潜在影响,同时也凸显了吸烟对其他疾病死亡率的重要影响。
{"title":"Impact of smoking on resected lung cancer depends on epidermal growth factor receptor mutation.","authors":"Keigo Sekihara, Akikazu Kawase, Yuta Matsubayashi, Tomoya Tajiri, Motohisa Shibata, Takamitsu Hayakawa, Norihiko Shiiya, Kazuhito Funai","doi":"10.1093/icvts/ivae109","DOIUrl":"10.1093/icvts/ivae109","url":null,"abstract":"<p><strong>Objectives: </strong>Smokers comprise the majority of surgical patients with primary lung cancer. Epidermal growth factor receptor (EGFR) mutation-negative status impacts the treatment of recurrence. However, the prognostic impact of cigarette smoking stratified by EGFR mutation status has not been reported. Therefore, we assessed its impact on patients with resected lung cancer.</p><p><strong>Methods: </strong>We retrospectively analysed 362 consecutive patients who underwent complete resection for stage 1 primary lung cancer at our institution between 2012 and 2021. The EGFR mutation status was evaluated using the real-time polymerase chain reaction. We compared the overall survival (OS) and disease-free survival (DFS) between patients with and without a history of smoking.</p><p><strong>Results: </strong>The EGFR mutation-negative group included 194 patients, of whom 160 (83%) had a history of smoking. Male sex (P < 0.01), forced expiratory volume in 1 s (P < 0.01) and adenocarcinoma (P < 0.01) showed significant differences between the groups. In the EGFR mutation-positive group, the 5-year OS and DFS were similar regardless of smoking status (OS: 86% vs 75%; DFS: 73% vs 73%). In the EGFR mutation-negative group, the 5-year OS and DFS were significantly poorer in the smoking group (OS: 87% vs 65%, P = 0.05; DFS: 84% vs 54%, P = 0.01). Deaths from other diseases were relatively high (n = 19, 53%).</p><p><strong>Conclusions: </strong>Cigarette smoking may be associated with a poor prognosis in EGFR mutation-negative lung cancer but had no impact on the prognosis of the EGFR mutation-positive group. This finding underscores the potential influence of smoking on the treatment of lung cancer recurrence but also highlights its significance in contributing to death from other diseases.</p>","PeriodicalId":73406,"journal":{"name":"Interdisciplinary cardiovascular and thoracic surgery","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11222299/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141294007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Digital Transformation in Thoracic Surgery: a survey among the European Society of Thoracic Surgeons. 胸外科的数字化转型:欧洲胸外科医师协会调查。
N/A CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-07-03 DOI: 10.1093/icvts/ivae119
Nora Mayer, George Sotiropoulos, Nuria Novoa, Niccolo Daddi, Hasan Batirel, Nizar Asadi

Objectives: Digital transformation has drastically changed the surgical sector, but few is known about its impact on thoracic surgical practice. The aim of this paper is to report the European Society of Thoracic Surgeons (ESTS) survey results, assessing the impact of and the need for Digital Transformation in Thoracic Surgery.

Methods: A 23-item survey was designed by the ESTS Digital Transformation Working Group to assess the impact of and the need for Digital Transformation in Thoracic Surgery. All ESTS members (1668) were invited to complete the survey between 13 March and 21 May 2022 anonymously. Data analysis was descriptive calculating frequencies and percentages. Group comparison was done using chi-square test.

Results: The response rate was 6.3%. Surgeons from 26 European countries participated of which more than 80% were based in academic hospitals. The impact of digital transformation was rated very important (43.8%) and fundamental (22.7%) in more than two-thirds of the cases, regardless of surgeons' age. None of the participants felt that digital transformation was of no importance and more than 85% had implemented digital platforms in their direct patient care. Almost 90% of the surgeons, currently not using digital platforms for training and education, would consider introducing them. About 70% were at least 'somewhat satisfied' with their current engagement in Digital Transformation in Thoracic Surgery.

Conclusions: Digital transformation seems to play a major role across European Thoracic Surgery departments in direct patient care, professional networking and surgical training. However, overall satisfaction with the current status of Digital Transformation in Thoracic Surgery was rather reserved, implying the need to increase the implementation of digital solutions in the latter.

目标:数字化转型极大地改变了外科领域,但人们对其对胸外科实践的影响知之甚少。本文旨在报告 ESTS 调查结果,评估胸外科数字化转型的影响和需求:ESTS 数字化转型工作组设计了一项包含 23 个项目的调查,以评估胸外科数字化转型的影响和需求。所有 ESTS 会员(1,668 名)受邀在 2022 年 3 月 13 日至 5 月 21 日期间匿名完成调查。数据分析采用描述性方法,计算频率和百分比。组间比较采用卡方检验:结果:回复率为 6.3%。来自 26 个欧洲国家的外科医生参与了调查,其中 80% 以上在学术医院工作。超过三分之二的外科医生认为数字化转型的影响非常重要(43.8%)和基本重要(22.7%),与外科医生的年龄无关。没有一位参与者认为数字化转型不重要,超过 85% 的参与者已在其直接的患者护理中实施了数字化平台。近 90% 的外科医生目前尚未使用数字平台进行培训和教育,但他们会考虑引入数字平台。约 70% 的外科医生对其目前参与胸外科数字化转型的情况至少 "有点满意":结论:数字化转型似乎在欧洲胸外科的直接患者护理、专业网络和手术培训中发挥着重要作用。然而,人们对胸外科数字化转型现状的总体满意度并不高,这意味着需要在胸外科加大数字化解决方案的实施力度。
{"title":"Digital Transformation in Thoracic Surgery: a survey among the European Society of Thoracic Surgeons.","authors":"Nora Mayer, George Sotiropoulos, Nuria Novoa, Niccolo Daddi, Hasan Batirel, Nizar Asadi","doi":"10.1093/icvts/ivae119","DOIUrl":"10.1093/icvts/ivae119","url":null,"abstract":"<p><strong>Objectives: </strong>Digital transformation has drastically changed the surgical sector, but few is known about its impact on thoracic surgical practice. The aim of this paper is to report the European Society of Thoracic Surgeons (ESTS) survey results, assessing the impact of and the need for Digital Transformation in Thoracic Surgery.</p><p><strong>Methods: </strong>A 23-item survey was designed by the ESTS Digital Transformation Working Group to assess the impact of and the need for Digital Transformation in Thoracic Surgery. All ESTS members (1668) were invited to complete the survey between 13 March and 21 May 2022 anonymously. Data analysis was descriptive calculating frequencies and percentages. Group comparison was done using chi-square test.</p><p><strong>Results: </strong>The response rate was 6.3%. Surgeons from 26 European countries participated of which more than 80% were based in academic hospitals. The impact of digital transformation was rated very important (43.8%) and fundamental (22.7%) in more than two-thirds of the cases, regardless of surgeons' age. None of the participants felt that digital transformation was of no importance and more than 85% had implemented digital platforms in their direct patient care. Almost 90% of the surgeons, currently not using digital platforms for training and education, would consider introducing them. About 70% were at least 'somewhat satisfied' with their current engagement in Digital Transformation in Thoracic Surgery.</p><p><strong>Conclusions: </strong>Digital transformation seems to play a major role across European Thoracic Surgery departments in direct patient care, professional networking and surgical training. However, overall satisfaction with the current status of Digital Transformation in Thoracic Surgery was rather reserved, implying the need to increase the implementation of digital solutions in the latter.</p>","PeriodicalId":73406,"journal":{"name":"Interdisciplinary cardiovascular and thoracic surgery","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11222297/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141473258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Implementation of cardiac enhanced recovery after surgery at Lausanne University Hospital, our roadbook to certification. 在洛桑大学医院实施心脏强化术后恢复,我们的认证路线图。
N/A CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-07-02 DOI: 10.1093/icvts/ivae118
Zied Ltaief, Mario Verdugo-Marchese, Dan Carel, Ziyad Gunga, Anna Nowacka, Valentine Melly, Valerie Addor, Caroline Botteau, Marius Hennemann, Luc Lavanchy, Matthias Kirsch, Valentina Rancati

Objectives: Enhanced recovery after surgery (ERAS) is a multidisciplinary, patient-centred approach aimed at expediting recovery, improving clinical outcomes, and reducing healthcare costs. Initially developed for colorectal surgery, ERAS principles have been successfully applied across various surgical specialties, including cardiac surgery. This study outlines the implementation and certification process of the ERAS program in a tertiary cardiac surgical centre within the Heart-Vessel Department at Lausanne University Hospital.

Methods: The implementation involved forming a multidisciplinary team, including cardiac surgeons, anaesthesiologists, intensivists, a cardiologist, clinical nurse specialists and physiotherapists. The ERAS nurse coordinator played a central role in organizing meetings, promoting the program, developing protocols, and collecting data. The certification process required adherence to ERAS guidelines, structured training and external evaluation. Key phases included pre-ERAS data collection, protocol dissemination, inclusion of the 1st patients, followed by analysis and full implementation.

Results: Achieving certification required maintaining a compliance rate of over 70% with established protocols. The process involved overcoming various barriers, such as inconsistent practices and the need for multidisciplinary collaboration. In this paper, we provide some solutions to these challenges, including team education, regular meetings and continuous feedback loops. Preliminary data from the initial cohort showed improvements in early mobilization, opioid use, respiratory complications and shorter hospital stays.

Conclusions: The successful implementation of the ERAS program at our institution demonstrates the feasibility and benefits of a structured, multidisciplinary approach in cardiac surgery. Continuous self-assessment and adherence to guidelines are essential for sustained improvement in patient outcomes and healthcare efficiency.

目标:术后强化恢复(ERAS)是一种以患者为中心的多学科方法,旨在加快恢复、改善临床效果并降低医疗成本。ERAS 原则最初是针对结直肠手术开发的,现已成功应用于包括心脏手术在内的各种外科专科。本研究概述了ERAS计划在洛桑大学医院心脏血管部三级心脏外科中心的实施和认证过程:实施过程中组建了一个多学科团队,包括心脏外科医生、麻醉师、重症监护医生、心脏科医生、临床护理专家和理疗师。ERAS 护士协调员在组织会议、推广计划、制定方案和收集数据方面发挥了核心作用。认证过程需要遵守ERAS指南、进行结构化培训和外部评估。关键阶段包括 ERAS 前期数据收集、方案宣传、纳入首批患者、分析和全面实施:要获得认证,就必须保持超过 70% 的符合率。在这一过程中,需要克服各种障碍,如做法不一致和需要多学科合作等。在本文中,我们针对这些挑战提出了一些解决方案,包括团队教育、定期会议和持续反馈循环。来自初始队列的初步数据显示,在早期动员、阿片类药物使用、呼吸系统并发症和缩短住院时间方面均有改善:我院ERAS计划的成功实施证明了在心脏外科采用结构化、多学科方法的可行性和益处。持续的自我评估和对指南的遵守对于持续改善患者预后和提高医疗效率至关重要。
{"title":"Implementation of cardiac enhanced recovery after surgery at Lausanne University Hospital, our roadbook to certification.","authors":"Zied Ltaief, Mario Verdugo-Marchese, Dan Carel, Ziyad Gunga, Anna Nowacka, Valentine Melly, Valerie Addor, Caroline Botteau, Marius Hennemann, Luc Lavanchy, Matthias Kirsch, Valentina Rancati","doi":"10.1093/icvts/ivae118","DOIUrl":"10.1093/icvts/ivae118","url":null,"abstract":"<p><strong>Objectives: </strong>Enhanced recovery after surgery (ERAS) is a multidisciplinary, patient-centred approach aimed at expediting recovery, improving clinical outcomes, and reducing healthcare costs. Initially developed for colorectal surgery, ERAS principles have been successfully applied across various surgical specialties, including cardiac surgery. This study outlines the implementation and certification process of the ERAS program in a tertiary cardiac surgical centre within the Heart-Vessel Department at Lausanne University Hospital.</p><p><strong>Methods: </strong>The implementation involved forming a multidisciplinary team, including cardiac surgeons, anaesthesiologists, intensivists, a cardiologist, clinical nurse specialists and physiotherapists. The ERAS nurse coordinator played a central role in organizing meetings, promoting the program, developing protocols, and collecting data. The certification process required adherence to ERAS guidelines, structured training and external evaluation. Key phases included pre-ERAS data collection, protocol dissemination, inclusion of the 1st patients, followed by analysis and full implementation.</p><p><strong>Results: </strong>Achieving certification required maintaining a compliance rate of over 70% with established protocols. The process involved overcoming various barriers, such as inconsistent practices and the need for multidisciplinary collaboration. In this paper, we provide some solutions to these challenges, including team education, regular meetings and continuous feedback loops. Preliminary data from the initial cohort showed improvements in early mobilization, opioid use, respiratory complications and shorter hospital stays.</p><p><strong>Conclusions: </strong>The successful implementation of the ERAS program at our institution demonstrates the feasibility and benefits of a structured, multidisciplinary approach in cardiac surgery. Continuous self-assessment and adherence to guidelines are essential for sustained improvement in patient outcomes and healthcare efficiency.</p>","PeriodicalId":73406,"journal":{"name":"Interdisciplinary cardiovascular and thoracic surgery","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11219240/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141422094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Robotic-assisted thoracic surgery training in France: a nation-wide survey from young surgeons. 法国的机器人辅助胸外科培训:对全国年轻外科医生的调查。
N/A CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-07-02 DOI: 10.1093/icvts/ivae115
Hugo Clermidy, Guillaume Fadel, Benjamin Bottet, Yaniss Belaroussi, Maroua Eid, Elsa Armand, Jean-Marc Baste, Pierre-Benoit Pages, Alex Fourdrain, Charles Al Zreibi, Leslie Madelaine, Gabriel Saiydoun

Objectives: Evaluate theoretical and practical training of thoracic surgeons-in-training in robotic-assisted thoracic surgery (RATS) in France.

Methods: A survey was distributed to thoracic surgeons-in-training in France from November 2022 to February 2023.

Results: We recruited 101 thoracic surgeons-in-training (77% response rate). Over half had access to a surgical robotics system at their current institution. Most (74%) considered robotic surgery training essential, 90% had attended a robotic procedure. Only 18% had performed a complete thoracic robotic procedure as the main operator. A complete RATS procedure was performed by 42% of fellows and 6% of residents. Of the remaining surgeons, 23% had performed part of a robotic procedure. Theoretical courses and simulation are well developed; 72% of residents and 91% of fellows had undergone simulation training in the operating room, at training facilities, or during congress amounting to <10 h (for 73% of the fellows and residents), 10-20 h (17%), 20-30 h (8%) or >30 h (3%). Access to RATS was ≥1 day/week in 71% of thoracic departments with robotic access. Fellows spent a median of 2 (IQR 1-3) semesters in departments performing robotic surgery. Compared with low-volume centres, trainees at high-volume centres performed significantly more complete robotic procedures (47% vs 13%; P = 0.001), as did fellows compared with residents.

Conclusions: Few young surgeons perform complete thoracic robotic procedures during practical training, and access remains centre dependent. Opportunities increase with seniority and exposure; however, increasing availability of robotic devices, theoretical formation, and simulation courses will increase opportunities.

目的评估法国在训胸外科医生在机器人辅助胸腔镜手术(RATS)方面的理论和实践培训:方法:在 2022 年 11 月至 2023 年 2 月期间向法国的胸外科培训医师发放调查问卷:我们招募了 101 名胸外科实习医生(回复率为 77%)。超过半数的人在其目前所在的机构使用过手术机器人系统。大多数人(74%)认为机器人手术培训必不可少,90%的人参加过机器人手术。只有18%的人作为主要操作者实施过完整的胸腔机器人手术。42%的研究员和6%的住院医生实施过完整的机器人胸腔手术。在其余的外科医生中,23%的人实施过部分机器人手术。理论课程和模拟训练发展良好;72%的住院医师和91%的研究员曾在手术室、培训机构或大会期间接受过30小时(3%)的模拟训练。在71%有机器人接入的胸外科中,使用RATS的时间≥1天/周。研究员在实施机器人手术的科室度过的时间中位数为2个学期(IQR 1-3)。与低手术量中心相比,高手术量中心的受训人员完成的完整机器人手术明显更多(47% vs 13%; p = 0.001),研究员与住院医师相比也是如此:结论:很少有年轻外科医生在实习培训期间进行完整的胸腔镜机器人手术,而且手术机会仍取决于培训中心。机会随着年资和接触面的增加而增加;不过,机器人设备、理论培训和模拟课程的增加将增加机会。
{"title":"Robotic-assisted thoracic surgery training in France: a nation-wide survey from young surgeons.","authors":"Hugo Clermidy, Guillaume Fadel, Benjamin Bottet, Yaniss Belaroussi, Maroua Eid, Elsa Armand, Jean-Marc Baste, Pierre-Benoit Pages, Alex Fourdrain, Charles Al Zreibi, Leslie Madelaine, Gabriel Saiydoun","doi":"10.1093/icvts/ivae115","DOIUrl":"10.1093/icvts/ivae115","url":null,"abstract":"<p><strong>Objectives: </strong>Evaluate theoretical and practical training of thoracic surgeons-in-training in robotic-assisted thoracic surgery (RATS) in France.</p><p><strong>Methods: </strong>A survey was distributed to thoracic surgeons-in-training in France from November 2022 to February 2023.</p><p><strong>Results: </strong>We recruited 101 thoracic surgeons-in-training (77% response rate). Over half had access to a surgical robotics system at their current institution. Most (74%) considered robotic surgery training essential, 90% had attended a robotic procedure. Only 18% had performed a complete thoracic robotic procedure as the main operator. A complete RATS procedure was performed by 42% of fellows and 6% of residents. Of the remaining surgeons, 23% had performed part of a robotic procedure. Theoretical courses and simulation are well developed; 72% of residents and 91% of fellows had undergone simulation training in the operating room, at training facilities, or during congress amounting to <10 h (for 73% of the fellows and residents), 10-20 h (17%), 20-30 h (8%) or >30 h (3%). Access to RATS was ≥1 day/week in 71% of thoracic departments with robotic access. Fellows spent a median of 2 (IQR 1-3) semesters in departments performing robotic surgery. Compared with low-volume centres, trainees at high-volume centres performed significantly more complete robotic procedures (47% vs 13%; P = 0.001), as did fellows compared with residents.</p><p><strong>Conclusions: </strong>Few young surgeons perform complete thoracic robotic procedures during practical training, and access remains centre dependent. Opportunities increase with seniority and exposure; however, increasing availability of robotic devices, theoretical formation, and simulation courses will increase opportunities.</p>","PeriodicalId":73406,"journal":{"name":"Interdisciplinary cardiovascular and thoracic surgery","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11219244/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141422095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Physical preconditioning on biventricular temporary mechanical circulatory support while awaiting heart transplantation. 在等待心脏移植期间,双心室临时机械循环支持的物理预处理。
N/A CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-06-05 DOI: 10.1093/icvts/ivae106
Anna Stegmann, Ruhi Yeter, Christoph Knosalla, Pia Lanmüller

Temporary mechanical circulatory support (tMCS) is increasingly used in patients with cardiogenic shock as a bridge to further treatment. We present the case of a 52-year-old female patient with biventricular heart failure who was bridged to heart transplantation employing biventricular tMCS through a non-femoral access. The 'groin-free' tMCS concept facilitates pre-habilitation while awaiting heart transplantation.

临时机械循环支持(tMCS)越来越多地用于心源性休克患者,作为进一步治疗的桥梁1。我们介绍了一例 52 岁的双心室心力衰竭女性患者的病例,她通过非股动脉通路使用双心室临时机械循环支持为心脏移植(HTx)搭建了桥梁。无腹股沟 "tMCS 概念有助于在等待心脏移植期间进行预稳定治疗。
{"title":"Physical preconditioning on biventricular temporary mechanical circulatory support while awaiting heart transplantation.","authors":"Anna Stegmann, Ruhi Yeter, Christoph Knosalla, Pia Lanmüller","doi":"10.1093/icvts/ivae106","DOIUrl":"10.1093/icvts/ivae106","url":null,"abstract":"<p><p>Temporary mechanical circulatory support (tMCS) is increasingly used in patients with cardiogenic shock as a bridge to further treatment. We present the case of a 52-year-old female patient with biventricular heart failure who was bridged to heart transplantation employing biventricular tMCS through a non-femoral access. The 'groin-free' tMCS concept facilitates pre-habilitation while awaiting heart transplantation.</p>","PeriodicalId":73406,"journal":{"name":"Interdisciplinary cardiovascular and thoracic surgery","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11249966/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141461167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Updated outcomes of surgical treatment for recurrent thymic tumour: a report from the Japanese nationwide database. 复发性胸腺瘤手术治疗的最新结果:日本全国数据库报告
Pub Date : 2024-06-05 DOI: 10.1093/icvts/ivae064
Tetsuya Mizuno, Toyofumi Fengshi Chen-Yoshikawa, Ichiro Yoshino, Meinoshin Okumura, Norihiko Ikeda, Koji Kuroda, Yoshimasa Maniwa, Masato Kanzaki, Makoto Suzuki

Objectives: This study aimed to analyse the surgical outcomes for recurrent thymic epithelial tumours and identify the factors associated with post-recurrence survival, using an updated Japanese nationwide database.

Methods: The cohort that developed recurrence after the initial resection was extracted from an updated database of patients whose thymic epithelial tumours were treated surgically between 1991 and 2010. Furthermore, we reviewed clinicopathological and prognostic factors of re-resected cases. Post-recurrence survival outcomes and cause-specific deaths in non-re-resected cases were also reviewed.

Results: We enrolled 191 patients who underwent re-resection and 259 patients who did not. In the surgery group, more patients with early stage disease, less aggressive World Health Organization (WHO) histological classification, initial complete resection and shorter recurrence-free intervals were included. Non-thymic carcinoma, absence of preoperative treatment, longer recurrent-free interval, single-site recurrence and R0-1 re-resection were all significantly favourable prognostic factors for post-recurrence survival in the surgery group, according to univariable analyses. Non-thymic carcinoma histology, longer recurrence-free interval and R0-1 re-resection were identified as independent prognostic factors according to multivariable analysis. The post-recurrence survival of the entire cohort with R2 re-resection was significantly better than that of the non-surgery group, although it was not demonstrated that patients with thymoma who underwent R2 re-resection had significantly better post-recurrence and lower cause-specific death.

Conclusions: R0-1 re-resection was newly identified as a prognostic factor after re-resection, in addition to non-thymic carcinoma histological classification and longer recurrence-free intervals, as documented in the initial report.

研究目的本研究旨在利用最新的日本全国数据库,分析胸腺上皮肿瘤复发的手术结果,并确定与复发后生存相关的因素:方法:我们从1991年至2010年间接受手术治疗的胸腺上皮肿瘤患者的最新数据库中提取了初次切除术后复发的患者队列。此外,我们还回顾了再切除病例的临床病理和预后因素。我们还回顾了非再切除病例的再切除后生存结果和特定原因死亡:我们招募了 191 名接受再切除手术的患者和 259 名未接受再切除手术的患者。在手术组中,早期疾病、侵袭性较低的世界卫生组织(WHO)组织学分类、初次完全切除和无复发间隔时间较短的患者较多。根据单变量分析,非胸腺癌、术前未接受治疗、无复发间隔时间较长、单部位复发和R0-1再次切除都是手术组复发后生存率的显著有利预后因素。根据多变量分析,非胸膜癌组织学、更长的无复发间隔和R0-1再切除被确定为独立的预后因素。接受R2再切除术的胸腺瘤患者复发后的生存率明显优于未接受手术组,但并不能证明接受R2再切除术的胸腺瘤患者复发后的生存率明显优于未接受手术组,也不能证明接受R2再切除术的胸腺瘤患者死因特异性较低:结论:R0-1再次切除术是再次切除术后的一个新的预后因素,此外还有非胸腺癌组织学分类和更长的无复发间隔,这在最初的报告中有记载。
{"title":"Updated outcomes of surgical treatment for recurrent thymic tumour: a report from the Japanese nationwide database.","authors":"Tetsuya Mizuno, Toyofumi Fengshi Chen-Yoshikawa, Ichiro Yoshino, Meinoshin Okumura, Norihiko Ikeda, Koji Kuroda, Yoshimasa Maniwa, Masato Kanzaki, Makoto Suzuki","doi":"10.1093/icvts/ivae064","DOIUrl":"10.1093/icvts/ivae064","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to analyse the surgical outcomes for recurrent thymic epithelial tumours and identify the factors associated with post-recurrence survival, using an updated Japanese nationwide database.</p><p><strong>Methods: </strong>The cohort that developed recurrence after the initial resection was extracted from an updated database of patients whose thymic epithelial tumours were treated surgically between 1991 and 2010. Furthermore, we reviewed clinicopathological and prognostic factors of re-resected cases. Post-recurrence survival outcomes and cause-specific deaths in non-re-resected cases were also reviewed.</p><p><strong>Results: </strong>We enrolled 191 patients who underwent re-resection and 259 patients who did not. In the surgery group, more patients with early stage disease, less aggressive World Health Organization (WHO) histological classification, initial complete resection and shorter recurrence-free intervals were included. Non-thymic carcinoma, absence of preoperative treatment, longer recurrent-free interval, single-site recurrence and R0-1 re-resection were all significantly favourable prognostic factors for post-recurrence survival in the surgery group, according to univariable analyses. Non-thymic carcinoma histology, longer recurrence-free interval and R0-1 re-resection were identified as independent prognostic factors according to multivariable analysis. The post-recurrence survival of the entire cohort with R2 re-resection was significantly better than that of the non-surgery group, although it was not demonstrated that patients with thymoma who underwent R2 re-resection had significantly better post-recurrence and lower cause-specific death.</p><p><strong>Conclusions: </strong>R0-1 re-resection was newly identified as a prognostic factor after re-resection, in addition to non-thymic carcinoma histological classification and longer recurrence-free intervals, as documented in the initial report.</p>","PeriodicalId":73406,"journal":{"name":"Interdisciplinary cardiovascular and thoracic surgery","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11193311/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141428483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of HTK-Custodiol and St-Thomas solution as cardiac preservation solutions on early and midterm outcomes following heart transplantation. HTK-Custodiol和圣托马斯溶液作为心脏移植术后心脏保存溶液对早期和中期效果的比较。
Pub Date : 2024-06-05 DOI: 10.1093/icvts/ivae093
Filip Dulguerov, Tamila Abdurashidowa, Emeline Christophel-Plathier, Lucian Ion, Ziyad Gunga, Valentina Rancati, Patrick Yerly, Piergiorgio Tozzi, Adelin Albert, Zied Ltaief, Samuel Rotman, Philippe Meyer, Karl Lefol, Roger Hullin, Matthias Kirsch

Objectives: The choice of the cardiac preservation solution for myocardial protection at time of heart procurement remains controversial and uncertainties persist regarding its effect on the early and midterm heart transplantation (HTx) outcomes. We retrospectively compared our adult HTx performed with 2 different solutions, in terms of hospital mortality, mid-term survival, inotropic score, primary graft dysfunction and rejection score.

Methods: From January 2009 to December 2020, 154 consecutive HTx of adult patients, followed up in pre- and post-transplantation by 2 different tertiary centres, were performed at the University Hospital of Lausanne, Switzerland. From 2009 to 2015, the cardiac preservation solution used was exclusively St-Thomas, whereafter an institutional decision was made to use HTK-Custodiol only. Patients were classified in 2 groups accordingly.

Results: There were 75 patients in the St-Thomas group and 79 patients in the HTK-Custodiol group. The 2 groups were comparable in terms of preoperative and intraoperative characteristics. Postoperatively, compared to the St-Thomas group, the Custodiol group patients showed significantly lower inotropic scores [median (interquartile range): 35.7 (17.5-60.2) vs 71.8 (31.8-127), P < 0.001], rejection scores [0.08 (0.0-0.25) vs 0.14 (0.05-0.5), P = 0.036] and 30-day mortality rate (2.5% vs 14.7%, P = 0.007) even after adjusting for potential confounders. Microscopic analysis of the endomyocardial biopsies also showed less specific histological features of subendothelial ischaemia (3.8% vs 17.3%, P = 0.006). There was no difference in primary graft dysfunction requiring postoperative extracorporeal membrane oxygenation. The use of HTK-Custodiol solution significantly improved midterm survival (Custodiol versus St-Thomas: hazard ratio = 0.20, 95% confidence interval: 0.069-0.60, P = 0.004).

Conclusions: This retrospective study comparing St-Thomas solution and HTK-Custodiol as myocardial protection during heart procurement showed that Custodiol improves outcomes after HTx, including postoperative inotropic score, rejection score, 30-day mortality and midterm survival.

目的:在采集心脏时选择何种心脏保存方案来保护心肌仍存在争议,而且其对早期和中期心脏移植结果的影响仍存在不确定性。我们从住院死亡率、中期存活率、肌力评分、原发性移植物功能障碍和排斥评分等方面,对采用两种不同方案进行的成人心脏移植手术进行了回顾性比较:方法:2009年1月至2020年12月,瑞士洛桑大学医院连续为154名成年患者进行了心脏移植手术,由两家不同的三级医疗中心进行移植前后的随访。从2009年到2015年,心脏保存液全部使用圣托马斯(St-Thomas),此后机构决定只使用HTK-Custodiol。患者相应地被分为两组:St-Thomas 组有 75 名患者,HTK-Custodiol 组有 79 名患者。两组患者在术前和术中特征方面具有可比性。术后,与 St-Thomas 组相比,Custodiol 组患者的肌力评分明显较低[中位数(四分位数间距):35.7(17.5-60)]:35.7 (17.5-60.2) vs 71.8 (31.8-127), p 结论:这项回顾性研究比较了St-Thomas溶液和HTK-Custodiol作为心脏采集过程中的心肌保护,结果表明Custodiol能改善心脏移植术后的预后,包括术后肌力评分、排斥评分、30天死亡率和中期存活率。
{"title":"Comparison of HTK-Custodiol and St-Thomas solution as cardiac preservation solutions on early and midterm outcomes following heart transplantation.","authors":"Filip Dulguerov, Tamila Abdurashidowa, Emeline Christophel-Plathier, Lucian Ion, Ziyad Gunga, Valentina Rancati, Patrick Yerly, Piergiorgio Tozzi, Adelin Albert, Zied Ltaief, Samuel Rotman, Philippe Meyer, Karl Lefol, Roger Hullin, Matthias Kirsch","doi":"10.1093/icvts/ivae093","DOIUrl":"10.1093/icvts/ivae093","url":null,"abstract":"<p><strong>Objectives: </strong>The choice of the cardiac preservation solution for myocardial protection at time of heart procurement remains controversial and uncertainties persist regarding its effect on the early and midterm heart transplantation (HTx) outcomes. We retrospectively compared our adult HTx performed with 2 different solutions, in terms of hospital mortality, mid-term survival, inotropic score, primary graft dysfunction and rejection score.</p><p><strong>Methods: </strong>From January 2009 to December 2020, 154 consecutive HTx of adult patients, followed up in pre- and post-transplantation by 2 different tertiary centres, were performed at the University Hospital of Lausanne, Switzerland. From 2009 to 2015, the cardiac preservation solution used was exclusively St-Thomas, whereafter an institutional decision was made to use HTK-Custodiol only. Patients were classified in 2 groups accordingly.</p><p><strong>Results: </strong>There were 75 patients in the St-Thomas group and 79 patients in the HTK-Custodiol group. The 2 groups were comparable in terms of preoperative and intraoperative characteristics. Postoperatively, compared to the St-Thomas group, the Custodiol group patients showed significantly lower inotropic scores [median (interquartile range): 35.7 (17.5-60.2) vs 71.8 (31.8-127), P < 0.001], rejection scores [0.08 (0.0-0.25) vs 0.14 (0.05-0.5), P = 0.036] and 30-day mortality rate (2.5% vs 14.7%, P = 0.007) even after adjusting for potential confounders. Microscopic analysis of the endomyocardial biopsies also showed less specific histological features of subendothelial ischaemia (3.8% vs 17.3%, P = 0.006). There was no difference in primary graft dysfunction requiring postoperative extracorporeal membrane oxygenation. The use of HTK-Custodiol solution significantly improved midterm survival (Custodiol versus St-Thomas: hazard ratio = 0.20, 95% confidence interval: 0.069-0.60, P = 0.004).</p><p><strong>Conclusions: </strong>This retrospective study comparing St-Thomas solution and HTK-Custodiol as myocardial protection during heart procurement showed that Custodiol improves outcomes after HTx, including postoperative inotropic score, rejection score, 30-day mortality and midterm survival.</p>","PeriodicalId":73406,"journal":{"name":"Interdisciplinary cardiovascular and thoracic surgery","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11150883/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141163015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Interdisciplinary cardiovascular and thoracic surgery
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1